Table 3.
Number of cases of influenza and influenza vaccine efficacy against first episodes of laboratory-confirmed influenza by type in women and their infants up to 5 months of age
|
Women |
Vaccine efficacy (95% CI) |
Infants |
Vaccine efficacy (95% CI) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| TIIV group (n=2108) | Incidence per 1000 person-days of follow-up | MCV group (n=2085) | Incidence per 1000 person-days of follow-up | TIIV group (n=2064) | Incidence per 1000 person-days of follow-up | MCV group (n=2041) | Incidence per 1000 person-days of follow-up | ||||
| Type A | 7 | 0·03 | 25 | 0·09 | 72·0% (35·2 to 87·9) | 17 | 0·06 | 48 | 0·17 | 64·5% (38·3 to 79·6) | |
| H3N2 | 4 | 0·01 | 7 | 0·03 | 42·8% (−95·4 to 83·3) | 10 | 0·04 | 27 | 0·10 | 62·9% (23·4 to 82·0) | |
| H1N1 | 3 | 0·01 | 18 | 0·06 | 83·3% (43·4 to 95·1) | 7 | 0·02 | 21 | 0·07 | 66·6% (21·5 to 85·8) | |
| Type B | 4 | 0·01 | 15 | 0·05 | 73·3% (19·6 to 91·1) | 8 | 0·03 | 10 | 0·04 | 19·9% (−103·0 to 68·4) | |
TIIV=trivalent inactivated influenza vaccine. MCV=quadrivalent meningococcal conjugate vaccine.